Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | ABL2 | P42684 | 1/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3231311 | 0.88 | SRC (0.72) | SRCABL1ABL2GAKEGFR | |
| SCHEMBL5254459 | 0.86 | SRC (0.62) | SRCABL1ABL2GAKEGFR | |
| SCHEMBL3219495 | 0.86 | SRC (0.67) | SRCABL1ABL2GAKEGFR | |
| SCHEMBL3233501 | 0.86 | SRC (0.83) | SRCABL1ABL2GAKEGFR | |
| SCHEMBL3213103 | 0.79 | SRC (0.85) | SRCABL1ABL2EGFRFYN | |
| SCHEMBL3229351 | 0.79 | SRC (0.75) | SRCABL1ABL2FYN | |
| SCHEMBL3225339 | 0.78 | SRC (0.73) | SRCGAKEGFRFYN | |
| SCHEMBL3226355 | 0.77 | SRC (0.79) | SRCABL1ABL2GAKEGFR | |
| SCHEMBL3225510 | 0.77 | SRC (0.75) | SRCGAKEGFRFYN | |
| SCHEMBL3224430 | 0.77 | SRC (0.75) | SRCABL1ABL2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010030835-A2 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | CYP19A1, SRC, CYP17A1 | SRC 2/4885ABL1 39/4885ABL2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.